EU CHMP recommends Roche’s Perjeta for pre-surgery use in breast cancer
The European Union (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended for approval Roche's Perjeta along with Herceptin and chemotherapy for neoadjuvant treatment of adult patients with HER2-positive early breast cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pharmaceuticals